Literature DB >> 10917520

Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha.

S C Garman1, B A Wurzburg, S S Tarchevskaya, J P Kinet, T S Jardetzky.   

Abstract

The initiation of immunoglobulin-E (IgE)-mediated allergic responses requires the binding of IgE antibody to its high-affinity receptor, Fc epsilonRI. Crosslinking of Fc epsilonRI initiates an intracellular signal transduction cascade that triggers the release of mediators of the allergic response. The interaction of the crystallizable fragment (Fc) of IgE (IgE-Fc) with Fc epsilonRI is a key recognition event of this process and involves the extracellular domains of the Fc epsilonRI alpha-chain. To understand the structural basis for this interaction, we have solved the crystal structure of the human IgE-Fc-Fc epsilonRI alpha complex to 3.5-A resolution. The crystal structure reveals that one receptor binds one dimeric IgE-Fc molecule asymmetrically through interactions at two sites, each involving one C epsilon3 domain of the IgE-Fc. The interaction of one receptor with the IgE-Fc blocks the binding of a second receptor, and features of this interaction are conserved in other members of the Fc receptor family. The structure suggests new approaches to inhibiting the binding of IgE to Fc epsilonRI for the treatment of allergy and asthma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10917520     DOI: 10.1038/35018500

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  94 in total

Review 1.  Mast cells. Receptors, secretagogues, and signaling.

Authors:  Bhavya B Sharma; John R Apgar; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor.

Authors:  Gerald R Nakamura; Mark E Reynolds; Yvonne M Chen; Melissa A Starovasnik; Henry B Lowman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

3.  An unusual Fc receptor-related protein expressed in human centroblasts.

Authors:  Fabio Facchetti; Marina Cella; Silvana Festa; Daved H Fremont; Marco Colonna
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

4.  The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

Authors:  I B Rasmussen; E Lunde; T E Michaelsen; B Bogen; I Sandlie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

Review 5.  Structure and function of natural-killer-cell receptors.

Authors:  Peter D Sun
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

6.  Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding.

Authors:  Jinghua Lu; Jeff L Ellsworth; Nels Hamacher; Si Won Oak; Peter D Sun
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

7.  SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE.

Authors:  A Zh Baltabekova; Zh S Shagyrova; A S Kamzina; M Voykov; Ye Zhiyenbay; E M Ramanculov; A V Shustov
Journal:  Mol Biotechnol       Date:  2015-08       Impact factor: 2.695

Review 8.  IgE and FcepsilonRI regulation.

Authors:  Donald MacGlashan
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

9.  Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors.

Authors:  Stephen L Sazinsky; René G Ott; Nathaniel W Silver; Bruce Tidor; Jeffrey V Ravetch; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

10.  Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding.

Authors:  Michelle M Gomes; Stephanie B Wall; Kazuo Takahashi; Jan Novak; Matthew B Renfrow; Andrew B Herr
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.